Skip to content
PubMed This is a summary of 95 peer-reviewed journal articles Updated

Research & Literature

Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.

Explore the Literature Visualize citation networks across 95 referenced papers

Top Authors

Ali T. Taher
American University of Beirut Medical Center
Maria Domenica Cappellini
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Antonis Kattamis
National and Kapodistrian University of Athens
Raffaella Origa
University of Cagliari
Deepak Bansal
Post Graduate Institute of Medical Education and Research
Vincenzo De Sanctis
University of Ferrara
Kevin H.M. Kuo
University of Toronto
Antonio Giulio Piga
University of Turin
Thomas D. Coates
University of Southern California
Ashraf Tawfik Soliman
Hamad General Hospital

Top Institutions

Ranked by publications Top 10 institutions

References

References (95)
  1. 1

    Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.

    Calvaruso G, Vitrano A, Di Maggio R, et al.

    American journal of hematology 2015; (90(7)):634-8 doi:10.1002/ajh.24024.

    PMID: 25809173
  2. 2

    Pulmonary hypertension in non-transfusion-dependent thalassemia: Correlation with clinical parameters, liver iron concentration, and non-transferrin-bound iron.

    Inthawong K, Charoenkwan P, Silvilairat S, et al.

    Hematology (Amsterdam, Netherlands) 2015; (20(10)):610-7 doi:10.1179/1607845415Y.0000000014.

    PMID: 25964094
  3. 3

    Serum Ferritin Levels Correlation With Heart and Liver MRI and LIC in Patients With Transfusion-Dependent Thalassemia.

    Majd Z, Haghpanah S, Ajami GH, et al.

    Iranian Red Crescent medical journal 2015; (17(4)):e24959 doi:10.5812/ircmj.17(4)2015.24959.

    PMID: 26023341
  4. 4

    Screening for common β-globin gene cluster deletions in Chinese individuals with increased hemoglobin F.

    Cai WJ, Li J, Xie XM, Li DZ

    International journal of laboratory hematology 2015; (37(6)):752-7 doi:10.1111/ijlh.12401.

    PMID: 26179971
  5. 5

    β-Thalassemia Intermedia Caused by Compound Heterozygosity for Hb Lepore-Hollandia and β-Thalassemia is Rare in the Indian Population.

    Sreedharanunni S, Chhabra S, Hira JK, et al.

    Hemoglobin 2015; (39(5)):362-5 doi:10.3109/03630269.2015.1064004.

    PMID: 26291970
  6. 6

    Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management.

    Vichinsky E

    Current medical research and opinion 2016; (32(1)):191-204 doi:10.1185/03007995.2015.1110128.

    PMID: 26479125
  7. 7

    Increasing prevalence of thalassemia in America: Implications for primary care.

    Sayani FA, Kwiatkowski JL

    Annals of medicine 2015; (47(7)):592-604 doi:10.3109/07853890.2015.1091942.

    PMID: 26541064
  8. 8

    Hb lepore/β0-thalassaemia with α+-thalassaemia interactions, a potential diagnostic pitfall.

    Alauddin H, Mohamad Nasir S, Ahadon M, et al.

    The Malaysian journal of pathology 2015; (37(3)):287-92.

    PMID: 26712677
  9. 9

    Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010.

    Baronciani D, Angelucci E, Potschger U, et al.

    Bone marrow transplantation 2016; (51(4)):536-41 doi:10.1038/bmt.2015.293.

    PMID: 26752139
  10. 10

    Corpuscular Haemolytic Anaemias - Lepore Haemoglobinopathy.

    Tudorascu I, Neamtu S, Stanca L, et al.

    Current health sciences journal 2014; (40(4)):281-4 doi:10.12865/CHSJ.40.04.10.

    PMID: 26793325
  11. 11

    Morbidities in non-transfusion-dependent thalassemia.

    Saliba AN, Taher AT

    Annals of the New York Academy of Sciences 2016; (1368(1)):82-94 doi:10.1111/nyas.13083.

    PMID: 27186941
  12. 12

    Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?

    Coates TD, Carson S, Wood JC, Berdoukas V

    Annals of the New York Academy of Sciences 2016; (1368(1)):95-106 doi:10.1111/nyas.13060.

    PMID: 27186942
  13. 13

    Medical complications following splenectomy.

    Buzelé R, Barbier L, Sauvanet A, Fantin B

    Journal of visceral surgery 2016; (153(4)):277-86.

    PMID: 27289254
  14. 14

    Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine.

    Hassan MA, Tolba OA

    Electronic physician 2016; (8(5)):2425-31 doi:10.19082/2425.

    PMID: 27382454
  15. 15

    Overwhelming post-splenectomy sepsis in patients with asplenia and hyposplenia: a retrospective cohort study.

    Chong J, Jones P, Spelman D, et al.

    Epidemiology and infection 2017; (145(2)):397-400 doi:10.1017/S0950268816002405.

    PMID: 27776576
  16. 16

    Invasive prenatal diagnosis of fetal thalassemia.

    Li DZ, Yang YD

    Best practice & research. Clinical obstetrics & gynaecology 2017; (39()):41-52 doi:10.1016/j.bpobgyn.2016.10.011.

    PMID: 27889305
  17. 17

    New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.

    Taher AT, Origa R, Perrotta S, et al.

    American journal of hematology 2017; (92(5)):420-428 doi:10.1002/ajh.24668.

    PMID: 28142202
  18. 18

    Molecular and clinical analysis of haemoglobin Lepore in Campania, a region of Southern Italy.

    Ricchi P, Ammirabile M, Spasiano A, et al.

    Hematology (Amsterdam, Netherlands) 2017; (22(7)):437-443 doi:10.1080/10245332.2017.1289304.

    PMID: 28218017
  19. 19

    Incomplete paraplegia caused by extramedullary hematopoiesis in a patient with thalassemia intermedia.

    Hisamud-Din N, Mustafah NM, Fauzi AA, Hashim NM

    Spinal cord series and cases 2017; (3()):17020 doi:10.1038/scsandc.2017.20.

    PMID: 28503326
  20. 20

    Biochemical and Molecular Analysis of the Hb Lepore Boston Washington in a Syrian Homozygous Child.

    Pirastru M, Manca L, Trova S, Mereu P

    BioMed research international 2017; (2017()):1261972 doi:10.1155/2017/1261972.

    PMID: 28553644
  21. 21

    Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment.

    Caocci G, Orofino MG, Vacca A, et al.

    American journal of hematology 2017; (92(12)):1303-1310 doi:10.1002/ajh.24898.

    PMID: 28850704
  22. 22

    Iron overload in thalassemia: different organs at different rates.

    Taher AT, Saliba AN

    Hematology. American Society of Hematology. Education Program 2017; (2017(1)):265-271 doi:10.1182/asheducation-2017.1.265.

    PMID: 29222265
  23. 23

    New therapeutic targets in transfusion-dependent and -independent thalassemia.

    Cappellini MD, Motta I

    Hematology. American Society of Hematology. Education Program 2017; (2017(1)):278-283 doi:10.1182/asheducation-2017.1.278.

    PMID: 29222267
  24. 24

    Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.

    Bou-Fakhredin R, Bazarbachi AH, Chaya B, et al.

    International journal of molecular sciences 2017; (18(12)) doi:10.3390/ijms18122778.

    PMID: 29261151
  25. 25

    Hydroxyurea for lifelong transfusion-dependent β-thalassemia: A meta-analysis.

    Algiraigri AH, Wright NAM, Paolucci EO, Kassam A

    Pediatric hematology and oncology 2017; (34(8)):435-448 doi:10.1080/08880018.2017.1354948.

    PMID: 29337597
  26. 26

    Vitamin D deficiency and its relationship with cardiac iron and function in patients with transfusion-dependent thalassemia at Chiang Mai University Hospital.

    Dejkhamron P, Wejaphikul K, Mahatumarat T, et al.

    Pediatric hematology and oncology 2018; (35(1)):52-59 doi:10.1080/08880018.2018.1424280.

    PMID: 29359982
  27. 27

    Molecular Characteristics of Hb New York [β113(G15)Val→Glu, HBB: c.341T>A] in Thailand.

    Chaibunruang A, Singha K, Srivorakun H, et al.

    Hemoglobin 2018; (42(1)):11-15 doi:10.1080/03630269.2018.1430586.

    PMID: 29464999
  28. 28

    Under-recognized Hypoparathyroidism in Thalassemia

    Tangngam H, Mahachoklertwattana P, Poomthavorn P, et al.

    Journal of clinical research in pediatric endocrinology 2018; (10(4)):324-330 doi:10.4274/jcrpe.0020.

    PMID: 29726397
  29. 29

    The burden of psychiatric illnesses in adult patients with beta-thalassemia: a 5-year nationwide inpatient evaluation in the United States.

    Patel K, Bhivandkar S, Desai R, Antin T

    Annals of hematology 2019; (98(4)):851-860 doi:10.1007/s00277-018-3557-5.

    PMID: 30488326
  30. 30

    Prevalence and Risk Factors for Cardiac and Liver Iron Overload in Adults with Thalassemia in Malaysia.

    Ngim CF, Lee MY, Othman N, et al.

    Hemoglobin 2019; (43(2)):95-100 doi:10.1080/03630269.2019.1599906.

    PMID: 31179787
  31. 31

    Thyroid Disorders in Homozygous β-Thalassemia: Current Knowledge, Emerging Issues and Open Problems.

    De Sanctis V, Soliman AT, Canatan D, et al.

    Mediterranean journal of hematology and infectious diseases 2019; (11(1)):e2019029 doi:10.4084/MJHID.2019.029.

    PMID: 31205633
  32. 32

    Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran.

    Bordbar M, Bozorgi H, Saki F, et al.

    Journal of endocrinological investigation 2019; (42(12)):1467-1476 doi:10.1007/s40618-019-01072-z.

    PMID: 31228105
  33. 33

    Challenges of blood transfusions in β-thalassemia.

    Shah FT, Sayani F, Trompeter S, et al.

    Blood reviews 2019; (37()):100588 doi:10.1016/j.blre.2019.100588.

    PMID: 31324412
  34. 34

    Thalassemia: Common Clinical Queries in Management.

    Lal A, Bansal D

    Indian journal of pediatrics 2020; (87(1)):75-81 doi:10.1007/s12098-019-03065-5.

    PMID: 31620986
  35. 35

    Arrhythmias and Sudden Cardiac Death in Beta-Thalassemia Major Patients: Noninvasive Diagnostic Tools and Early Markers.

    Russo V, Melillo E, Papa AA, et al.

    Cardiology research and practice 2019; (2019()):9319832 doi:10.1155/2019/9319832.

    PMID: 31885907
  36. 36

    A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.

    Cappellini MD, Viprakasit V, Taher AT, et al.

    The New England journal of medicine 2020; (382(13)):1219-1231 doi:10.1056/NEJMoa1910182.

    PMID: 32212518
  37. 37

    Complications in the adult asplenic patient: A review for the emergency clinician.

    Long B, Koyfman A, Gottlieb M

    The American journal of emergency medicine 2021; (44()):452-457 doi:10.1016/j.ajem.2020.03.049.

    PMID: 32247651
  38. 38

    For Debate: Assessment of HbA1c in Transfusion Dependent Thalassemia Patients.

    De Sanctis V, Soliman AT, Daar S, et al.

    Pediatric endocrinology reviews : PER 2020; (17(3)):226-234 doi:10.17458/per.vol17.2020.fd.ssd.HbA1cthalassemia.

    PMID: 32741153
  39. 39

    The Trabecular Bone Score as a Predictor for Thalassemia-Induced Vertebral Fractures in Northeastern Thailand.

    Teawtrakul N, Chukanhom S, Charoensri S, et al.

    Anemia 2020; (2020()):4634709 doi:10.1155/2020/4634709.

    PMID: 32774916
  40. 40

    Fertility and pregnancy in Iranian thalassemia patients: An update on transfusion complications.

    Takhviji V, Zibara K, Azarkeivan A, et al.

    Transfusion medicine (Oxford, England) 2020; (30(5)):352-360 doi:10.1111/tme.12707.

    PMID: 32820581
  41. 41

    Overwhelming Post-Splenectomy Infection Syndrome: Variability in Timing With Similar Presentation.

    Gupta AK, Vazquez OA

    Cureus 2020; (12(8)):e9914 doi:10.7759/cureus.9914.

    PMID: 32968576
  42. 42

    Genotypic groups as risk factors for cardiac magnetic resonance abnormalities and complications in thalassemia major: a large, multicentre study.

    Pistoia L, Meloni A, Ricchi P, et al.

    Blood transfusion = Trasfusione del sangue 2021; (19(2)):168-176 doi:10.2450/2020.0023-20.

    PMID: 33000750
  43. 43

    Comparison of Two High-Pressure Liquid Chromatography Instruments Bio-Rad Variant-II and Tosoh HLC-723G11 in the Evaluation of Hemoglobinopathies.

    Chopra P, Bhardwaj S, Negi P, Arora A

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2020; (36(4)):725-732 doi:10.1007/s12288-020-01298-5.

    PMID: 33100717
  44. 44

    Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.

    Pinto VM, Forni GL

    International journal of molecular sciences 2020; (21(22)) doi:10.3390/ijms21228771.

    PMID: 33233561
  45. 45

    The use of luspatercept for thalassemia in adults.

    Cappellini MD, Taher AT

    Blood advances 2021; (5(1)):326-333 doi:10.1182/bloodadvances.2020002725.

    PMID: 33570654
  46. 46

    Extramedullary Hematopoiesis Causing Spinal Cord Compression.

    Judy BF, Jin Y, Sciubba DM

    World neurosurgery 2021; (149()):51-52 doi:10.1016/j.wneu.2021.02.023.

    PMID: 33601081
  47. 47

    Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major.

    Nuzzi R, Geronazzo G, Tridico F, et al.

    Clinical ophthalmology (Auckland, N.Z.) 2021; (15()):2099-2109 doi:10.2147/OPTH.S300974.

    PMID: 34045846
  48. 48

    Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development.

    Porter J, Taher A, Viprakasit V, et al.

    Expert review of hematology 2021; (14(7)):633-644 doi:10.1080/17474086.2021.1935854.

    PMID: 34324404
  49. 49

    Quality of Life and Related Paraclinical Factors in Iranian Patients with Transfusion-Dependent Thalassemia.

    Khodashenas M, Mardi P, Taherzadeh-Ghahfarokhi N, et al.

    Journal of environmental and public health 2021; (2021()):2849163 doi:10.1155/2021/2849163.

    PMID: 34457009
  50. 50

    Homozygous Hemoglobin Lepore: A Rare Condition Seen in a Bangladeshi Family.

    Aziz MA, Khan WA, Das SA, Banu B

    Mymensingh medical journal : MMJ 2021; (30(4)):1172-1176.

    PMID: 34605493
  51. 51

    Genetic and non-genetic factors affecting hemoglobin A2 expression in a large cohort of Thai individuals: implication for population screening for thalassemia.

    Singha K, Sanchaisuriya K, Fucharoen G, Fucharoen S

    American journal of translational research 2021; (13(10)):11632-11642.

    PMID: 34786089
  52. 52

    High prevalence of central hypothyroidism among patients with transfusion dependent thalassemia in Hospital Pulau Pinang: A cross sectional study.

    Seow CE, Goh AS, Lim SL

    The Medical journal of Malaysia 2021; (76(6)):799-803.

    PMID: 34806663
  53. 53

    Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study.

    Bayraktaroglu S, Karadas N, Onen S, et al.

    Annals of hematology 2022; (101(3)):521-529 doi:10.1007/s00277-021-04748-w.

    PMID: 34985558
  54. 54

    Activation of STAT and SMAD Signaling Induces Hepcidin Re-Expression as a Therapeutic Target for β-Thalassemia Patients.

    Saad HKM, Abd Rahman AA, Ab Ghani AS, et al.

    Biomedicines 2022; (10(1)) doi:10.3390/biomedicines10010189.

    PMID: 35052868
  55. 55

    A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia.

    Yasara N, Wickramarathne N, Mettananda C, et al.

    Scientific reports 2022; (12(1)):2752 doi:10.1038/s41598-022-06774-8.

    PMID: 35177777
  56. 56

    Alpha- and Beta-thalassemia: Rapid Evidence Review.

    Baird DC, Batten SH, Sparks SK

    American family physician 2022; (105(3)):272-280.

    PMID: 35289581
  57. 57

    [Clinical Diagnosis and Prenatal Screening of Hb Lepore-BW Associated with IVS-II-654 Heterozygous Mutation].

    Bai HL, Cheng W, Cui J, et al.

    Zhongguo shi yan xue ye xue za zhi 2022; (30(2)):529-533 doi:10.19746/j.cnki.issn.1009-2137.2022.02.034.

    PMID: 35395991
  58. 58

    Prevalence and risk factors of fractures in transfusion dependent thalassemia - A Hong Kong Chinese population cohort.

    Lee SLK, Wong RSM, Li CK, Leung WK

    Endocrinology, diabetes & metabolism 2022; (5(4)):e340 doi:10.1002/edm2.340.

    PMID: 35490138
  59. 59

    2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia.

    Farmakis D, Porter J, Taher A, et al.

    HemaSphere 2022; (6(8)):e732 doi:10.1097/HS9.0000000000000732.

    PMID: 35928543
  60. 60

    Homozygous Lepore Syndrome: A case report.

    Bhusal A, Bhandari S, Seth T, Sah RP

    Annals of medicine and surgery (2012) 2022; (80()):104168 doi:10.1016/j.amsu.2022.104168.

    PMID: 36045803
  61. 61

    Thalassemia Intermedia: Chelator or Not?

    Lee YC, Yen CT, Lee YL, Chen RJ

    International journal of molecular sciences 2022; (23(17)) doi:10.3390/ijms231710189.

    PMID: 36077584
  62. 62

    Understanding the Association between Red Blood Cell Transfusion Utilization and Humanistic and Economic Burden in Patients with β-Thalassemia from the Patients' Perspective.

    Knoth RL, Gupta S, Perkowski K, et al.

    Journal of clinical medicine 2023; (12(2)) doi:10.3390/jcm12020414.

    PMID: 36675342
  63. 63

    Identification of rare thalassemia variants using third-generation sequencing.

    Liu Q, Chen Q, Zhang Z, et al.

    Frontiers in genetics 2022; (13()):1076035 doi:10.3389/fgene.2022.1076035.

    PMID: 36685902
  64. 64

    Fertility and Pregnancy in Women with Transfusion-Dependent Thalassemia.

    Sayani FA, Singer ST, Carlberg KT, Vichinsky EP

    Hematology/oncology clinics of North America 2023; (37(2)):393-411 doi:10.1016/j.hoc.2022.12.008.

    PMID: 36907611
  65. 65

    Desire for biological parenthood and patient counseling on the risk of infertility among adolescents and adults with hemoglobinopathies.

    Radauer-Plank AC, Diesch-Furlanetto T, Schneider M, et al.

    Pediatric blood & cancer 2023; (70(7)):e30359 doi:10.1002/pbc.30359.

    PMID: 37057367
  66. 66

    Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.

    Musallam KM, Taher AT, Kattamis A, et al.

    Drug design, development and therapy 2023; (17()):1583-1591 doi:10.2147/DDDT.S368584.

    PMID: 37255740
  67. 67

    Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START).

    Elalfy MS, Hamdy M, Adly A, et al.

    American journal of hematology 2023; (98(9)):1415-1424 doi:10.1002/ajh.27010.

    PMID: 37401738
  68. 68

    Carrier Screening Programs for Cystic Fibrosis, Fragile X Syndrome, Hemoglobinopathies and Thalassemia, and Spinal Muscular Atrophy: A Health Technology Assessment.

    Ontario health technology assessment series 2023; (23(4)):1-398.

    PMID: 37637488
  69. 69

    Rare occurrence of hemoglobin Lepore variant in a Palestinian patient: a case report and brief literature review.

    Asees MY, Shrateh ON, Jobran AWM, Assi AS

    Annals of medicine and surgery (2012) 2023; (85(10)):5219-5222 doi:10.1097/MS9.0000000000001212.

    PMID: 37811104
  70. 70

    Severe iron overload cardiomyopathy manifested as acute myopericarditis: A case report.

    Kosum P, Theerasuwipakorn N, Wicheantawatchai A, et al.

    Radiology case reports 2024; (19(1)):290-295 doi:10.1016/j.radcr.2023.10.020.

    PMID: 38028286
  71. 71

    Identification of Hb Lepore, Hb anti-Lepore, and α-globin gene triplications by long-read single-molecule real-time sequencing.

    Xu A, Ye Y, Huang Y, et al.

    American journal of clinical pathology 2024; (161(4)):411-417 doi:10.1093/ajcp/aqad155.

    PMID: 38037185
  72. 72

    Pregnancy outcomes and iron status in β-thalassemia major and intermedia: a systematic review and meta-analysis.

    Vlachodimitropoulou E, Mogharbel H, Kuo KHM, et al.

    Blood advances 2024; (8(3)):746-757 doi:10.1182/bloodadvances.2023011636.

    PMID: 38181780
  73. 73

    Revisiting iron overload status and change thresholds as predictors of mortality in transfusion-dependent β-thalassemia: a 10-year cohort study.

    Musallam KM, Barella S, Origa R, et al.

    Annals of hematology 2024; (103(7)):2283-2297 doi:10.1007/s00277-024-05715-x.

    PMID: 38503936
  74. 74

    Health-Related Quality-of-Life Impacts Associated with Transfusion-Dependent β-Thalassemia in the USA and UK: A Qualitative Assessment.

    Drahos J, Boateng-Kuffour A, Calvert M, et al.

    The patient 2024; (17(4)):421-439 doi:10.1007/s40271-024-00678-7.

    PMID: 38530509
  75. 75

    Molecular characterization of similar Hb Lepore Boston-Washington in four Chinese families using third generation sequencing.

    Zhuang J, Zhang N, Zheng Y, et al.

    Scientific reports 2024; (14(1)):9966 doi:10.1038/s41598-024-60604-7.

    PMID: 38693200
  76. 76

    Compound heterozygous with Hb G-Taipei and Hb Lepore-Boston-Washington: An unexpected finding triggered by HbA1c measurement.

    Li Y, Xu A, He J, et al.

    Practical laboratory medicine 2024; (39()):e00379 doi:10.1016/j.plabm.2024.e00379.

    PMID: 38715657
  77. 77

    Prevalence and risk factors predisposing low bone mineral density in patients with thalassemia.

    Ananvutisombat N, Tantiworawit A, Punnachet T, et al.

    Frontiers in endocrinology 2024; (15()):1393865 doi:10.3389/fendo.2024.1393865.

    PMID: 38978629
  78. 78

    The Relevance of β-Thalassemia Heterozygosity in Pediatric Clinical Practice: Croatian Experience.

    Dordevic A, Ugrin M, Sutic IM, et al.

    Children (Basel, Switzerland) 2024; (11(7)) doi:10.3390/children11070785.

    PMID: 39062234
  79. 79

    Gene therapy in transfusion-dependent non-β0/β0 genotype β-thalassemia: first real-world experience of beti-cel.

    Mirza A, Ritsert ML, Tao G, et al.

    Blood advances 2025; (9(1)):29-38 doi:10.1182/bloodadvances.2024014104.

    PMID: 39418614
  80. 80

    Epidural Spinal Cord Compression due to Extramedullary Hematopoiesis: Systematic Review of the Literature with an Illustrative Case.

    Lam NG, Ahmadpour A, Gimelfarb A, et al.

    World neurosurgery 2025; (193()):119-130 doi:10.1016/j.wneu.2024.10.034.

    PMID: 39427876
  81. 81

    Estimation of HbA1c Levels in Transfusion-Dependent Thalassemia Patients in Comparison With Normal Healthy Individuals.

    Bhatti PK, Ghay R, Singh Narang G, et al.

    Cureus 2024; (16(11)):e73236 doi:10.7759/cureus.73236.

    PMID: 39651019
  82. 82

    Long-term complications, survival and mortality in splenectomised adult transfusion-dependent thalassemia patients.

    Bhattacharjee U, Khadwal A, Singh C, et al.

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2025; (64(1)):104064 doi:10.1016/j.transci.2024.104064.

    PMID: 39787843
  83. 83

    A Multicenter ICET-A Survey on Adherence to Annual Oral Glucose Tolerance Test (OGTT) Screening in Transfusion-Dependent Thalassemia (TDT) Patients - The Expert Clinicians' Opinion on Factors Influencing the Adherence and on Alternative Strategies for Adherence Optimization.

    de Sanctis V, Canatan D, Daar S, et al.

    Mediterranean journal of hematology and infectious diseases 2025; (17(1)):e2025008 doi:10.4084/MJHID.2025.008.

    PMID: 39830799
  84. 84

    International Consensus Guideline on the Diagnosis and Management of Endocrine Complications of β and α Thalassemia in Children and Adolescents.

    Habeb A, Deeb A, Hamza RT, et al.

    Hormone research in paediatrics 2026; (99(7)):931-954 doi:10.1159/000546904.

    PMID: 40555215
  85. 85

    Beyond the blood: A practical guide to thalassemia care in the emergency department.

    Mufarrij A, Hodroj MH, Charbel N, et al.

    Blood reviews 2025; (74()):101327 doi:10.1016/j.blre.2025.101327.

    PMID: 40769855
  86. 86

    Endocrine dysfunction in homozygous beta-thalassemia: An underrecognized and undertreated consequence of prolonged survival.

    Savvidis C, Ilias I

    World journal of clinical cases 2025; (13(24)):107612 doi:10.12998/wjcc.v13.i24.107612.

    PMID: 40862198
  87. 87

    Novel Red Blood Cell Exchange Parameters for Treatment of Transfusion-Dependent Thalassemia Based on Experience of Five Patients.

    Sevcik K, Jackson C, Williams SM, et al.

    Journal of hematology 2025; (14(4)):210-213 doi:10.14740/jh2086.

    PMID: 40904934
  88. 88

    Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support.

    Inam Z, Han H, Webb J, Delaney M

    Transfusion medicine reviews 2025; (39(4)):150930 doi:10.1016/j.tmrv.2025.150930.

    PMID: 41223813
  89. 89

    A multi-center clinical trial of allogeneic hematopoietic stem cell transplantation in transfusion-dependent thalassemia.

    Liu R, Xiao H, Qin C, et al.

    Nature communications 2026; (17(1)).

    PMID: 41730859
  90. 90

    Curative Approach to the Treatment of Beta-Thalassemia and Sickle Cell Disease with Hematopoietic Stem Cell Transplantation.

    Testa U, Castelli G, Pelosi E

    Journal of clinical medicine 2026; (15(4)) doi:10.3390/jcm15041379.

    PMID: 41753067
  91. 91

    Current therapeutic landscape of β-thalassemia: focus on gene therapy.

    Cheng AN, Kwiatkowski JL

    Therapeutic advances in rare disease 2026; (7()):26330040261433028 doi:10.1177/26330040261433028.

    PMID: 41919270
  92. 92

    Overwhelming Post-Splenectomy Infection: A Case Report With Cause and Manner of Death Considerations.

    Newman JL, Gilson TP

    Academic forensic pathology 2026; 19253621261460506 doi:10.1177/19253621261460506.

    PMID: 42317492
  93. 93

    Diagnosis and Management of Transfusion-Dependent Thalassemia: Evidence-Based Guidelines From the Pediatric Hematology Oncology Chapter of the Indian Academy of Pediatrics.

    Radhakrishnan N, Dewan P, Chandra J, et al.

    Indian pediatrics 2026; (63(9)):612-637 doi:10.1007/s13312-026-00366-9.

    PMID: 42490030
  94. 94

    Precision Medicine in Transfusion-Dependent and Non-Transfusion-Dependent β-Thalassemia: Toward Personalized Diagnosis and Therapy.

    Karen AA, Tluli O, Hashem IE, et al.

    Hemoglobin 2026; (50(5)):405-413 doi:10.1080/03630269.2026.2709700.

    PMID: 42572810
  95. 95

    Transfusion Management in Pregnancies Complicated by Hemoglobinopathies: Evidence, Guidelines, and Clinical Challenges.

    Delicou S, Xydaki A, Moraki M, et al.

    Maternal-fetal medicine (Wolters Kluwer Health, Inc.) 2026; (8(4)):406-416 doi:10.1097/FM9.0000000000000353.

    PMID: 42936835